What You Should Know
Parexel has introduced ParexelAI™, a proprietary suite of human-led AI services designed to accelerate clinical development operations.Quantified Efficiencies: The suite is already delivering a 50% reduction in site selection timelines, a 30% reduction in medical writing for Clinical Study Reports, and a 20% reduction in safety literature screening.Regulatory Acceleration: Through a strategic partnership with Weave Bio, Parexel is reducing Investigational New Drug (IND)
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Roche Acquires PathAI to Automate Cancer Diagnostics in $1B Deal
What You Should Know
Global healthcare leader Roche has entered into a definitive merger agreement to acquire US-based digital pathology pioneer PathAI for an upfront purchase price of $750M, with up to $300M in additional milestone payments.The acquisition marks the culmination of a deep strategic partnership first established between the two companies in 2021 and expanded in 2024 to co-develop AI-enabled companion diagnostic algorithms.PathAI’s flagship AISight Image Management System (IMS)
Read More
Axoft Secures $55M for Implantable Brain-Computer Interfaces and Fleuron™ Material Global Trials
What You Should Know
Axoft has raised an oversubscribed $55M Series A led by C.P. Group Innovation, bringing its total funding to over $60M.The capital will be used to expand global clinical trials, progress U.S. regulatory approval for its implantable Brain-Computer Interfaces (iBCIs), and build a GMP manufacturing facility in Cambridge, MA.Axoft’s iBCIs utilize a proprietary material called Fleuron™, which is 10,000x softer than traditional polyimide, significantly reducing tissue scarring
Read More
CareDx to Acquire Naveris for $160M to Expand into HPV-Driven Cancer MRD Monitoring
What You Should Know
CareDx has entered into a definitive agreement to acquire Naveris, a precision oncology company specializing in blood-based monitoring for viral-mediated cancers.The deal includes $160M in up-front cash, with potential for an additional $100M based on future revenue milestones.Naveris’ flagship platform utilizes Tumor Tissue Modified Viral (TTMV®) DNA to detect and monitor HPV-driven cancers with high accuracy.The acquisition is expected to close in the third quarter of
Read More
Weave Bio Launches AI-Native NDA Submission Support in Strategic Partnership with Parexel
What You Should Know
Weave Bio has expanded its AI-native regulatory platform to support New Drug Application (NDA) submissions, covering the full drug development lifecycle.Strategic partner Parexel co-developed and refined the platform, resulting in authoring speeds that are 60% faster than traditional manual methods.The platform utilizes AI-native data extraction, content verification, and automated authoring to synthesize clinical, non-clinical, and manufacturing data.Parexel will
Read More
Moderna Deploys Salesforce Agentforce Life Sciences to Unify Global Commercial Operations
What You Should Know
Moderna has selected Salesforce’s Agentforce Life Sciences to serve as its unified, global platform for commercial operations and customer engagement.The platform will consolidate data from SAP, ecommerce, and regional systems to create a single "Customer 360" source of truth for all healthcare provider (HCP) interactions.Field teams will utilize AI-powered agents to automate cycle planning, deliver "next best action" recommendations, and streamline real-time call
Read More
FDA Announces Real-Time Clinical Trial Pilot Program and Proof-of-Concept Studies with AstraZeneca and Amgen
What You Should Know
The FDA has launched two proof-of-concept (PoC) real-time clinical trials (RTCT) that report endpoints and data signals to the agency as they occur.AstraZeneca is leading a Phase 2 trial (TRAVERSE) for mantle cell lymphoma, while Amgen is conducting a Phase 1b trial (STREAM-SCLC) for small cell lung carcinoma.The initiative aims to eliminate the traditional "hiatus" between clinical phases, moving toward a model of "continuous" trials that reduces regulatory lag.A Request
Read More
Accenture Ventures Invests in Iridius to Scale Compliant-by-Design AI for Life Sciences and Pharmaceuticals
What You Should Know
Accenture Ventures has made a strategic investment in Iridius, an enterprise AI infrastructure company specializing in compliant-by-design solutions for highly regulated industries.The partnership will build end-to-end compliance workflows across the life sciences value chain, covering regulatory submissions, pharmacovigilance, and clinical operations.Iridius technology uses a knowledge engine to translate complex global regulatory standards into machine-readable logic,
Read More
Courier Health Raises $50M to Solve Biopharma’s Data Fragmentation
The Biopharma Bottleneck: Why Courier Health Raised $50M to Fix Fragmented Patient Journeys
What You Should Know
The Funding: New York-based Courier Health has closed a $50 million Series B funding round led by Oak HC/FT, with participation from existing investors Norwest and Work-Bench.The Clinical Disconnect: Despite massive clinical innovation in life sciences, getting patients prescribed to actually start and stay on their medications is a logistical nightmare. According to the 2026
Read More
ViewsML Raises $4.9M for AI-Driven Virtual Biomarker Staining Platform
What You Should Know
The Funding: ViewsML, a company building the computational layer for biomarker discovery, has closed an oversubscribed $4.9M seed round led by Wittington Ventures, with significant strategic participation from Mayo Clinic and Continuum Health Ventures, alongside repeat investors like RiSC Capital and Debiopharm.The Core Technology: ViewsML is building the world’s first virtual biomarker library. Using artificial intelligence, the platform generates per-cell biomarker
Read More
